- Home
- ZURA vs PRQR Comparison
ZURA vs PRQR Comparison
Compare ZURA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- PRQR
- Stock Information
- Founded
- ZURA 2022
- PRQR 2012
- Country
- ZURA United States
- PRQR Netherlands
- Employees
- ZURA N/A
- PRQR N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ZURA Health Care
- PRQR Health Care
- Exchange
- ZURA Nasdaq
- PRQR Nasdaq
- Market Cap
- ZURA 69.9M
- PRQR 232.8M
- IPO Year
- ZURA N/A
- PRQR 2014
- Fundamental
- Price
- ZURA $1.92
- PRQR $1.99
- Analyst Decision
- ZURA Buy
- PRQR Strong Buy
- Analyst Count
- ZURA 10
- PRQR 8
- Target Price
- ZURA $12.67
- PRQR $8.88
- AVG Volume (30 Days)
- ZURA 334.1K
- PRQR 378.7K
- Earning Date
- ZURA 11-06-2025
- PRQR 11-06-2025
- Dividend Yield
- ZURA N/A
- PRQR N/A
- EPS Growth
- ZURA N/A
- PRQR N/A
- EPS
- ZURA N/A
- PRQR N/A
- Revenue
- ZURA N/A
- PRQR $20,129,184.00
- Revenue This Year
- ZURA N/A
- PRQR N/A
- Revenue Next Year
- ZURA N/A
- PRQR N/A
- P/E Ratio
- ZURA N/A
- PRQR N/A
- Revenue Growth
- ZURA N/A
- PRQR 8.65
- 52 Week Low
- ZURA $0.97
- PRQR $1.07
- 52 Week High
- ZURA $5.07
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ZURA 50.23
- PRQR 37.36
- Support Level
- ZURA $1.97
- PRQR $2.21
- Resistance Level
- ZURA $2.19
- PRQR $2.50
- Average True Range (ATR)
- ZURA 0.15
- PRQR 0.15
- MACD
- ZURA -0.03
- PRQR -0.03
- Stochastic Oscillator
- ZURA 10.00
- PRQR 4.63
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.